Literature DB >> 10808060

Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes.

T Yamada1, A Sato, T Nishimori, T Mitsuhashi, A Terao, H Sagai, M Komatsu, T Aizawa, K Hashizume.   

Abstract

To critically evaluate the relative importance of coagulation abnormalities over other clinical variables for micro- and macrovascular diabetic complications, prothrombin fragment (F1+2), thrombin-antithrombin III complex (TAT), fibrin degradation product d-dimer, and alpha2 plasmin inhibitor complex were determined in 101 stable, relatively well controlled patients with Type 2 diabetes (the mean HbA1c, age and duration of diabetes, 7.1%, 61 and 7.5 years, respectively). First, incidence and severity of diabetic micro- and macroangiopathies were progressively increased with the severity of coagulation abnormalities. Next, correlation of the four values with the presence of micro- and macrovascular complications, respectively, was analyzed by the multiple logistic regression analysis, with the inclusion of other variables such as age, duration of diabetes, HbA1c, blood pressure, and urinary albumin excretion. With the presence of microangiopathies, F1+2 and systolic blood pressure were significantly related, with the relationship being very strong for the former (P=0.003) and weak for the latter (P=0.035). On the other hand, with the presence of macroangiopathies, F1+2 (P=0.003), TAT (P=0.002), duration of diabetes (P=0.015), and age (P=0.013) were related. Other clinical variables were not significantly related with the presence of complications. Coagulation and fibrinolytic abnormalities are stronger determinants of the presence of diabetic vascular complications than other clinical variables including the degree of glycemia, in stable, relatively well controlled patients with Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10808060     DOI: 10.1016/s0168-8227(00)00134-0

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  5 in total

1.  Clinical utility of the ratio between circulating fibrinogen and fibrin (ogen) degradation products for evaluating coronary artery disease in type 2 diabetic patients.

Authors:  Wei-Xin Xiong; Ying Shen; Dao-Peng Dai; Lin Lu; Qi Zhang; Rui-Yan Zhang; Wei-Feng Shen; Rong Tao
Journal:  Chin Med J (Engl)       Date:  2015-03-20       Impact factor: 2.628

2.  Effect of poor glycaemic control on plasma levels and activity of protein C, protein S, and antithrombin III in type 2 diabetes mellitus.

Authors:  Otchere Addai-Mensah; Max Efui Annani-Akollor; Frederick Obeng Nsafoah; Linda Ahenkorah Fondjo; Eddie-Williams Owiredu; Kwabena Owusu Danquah; Richard Vikpebah Duneeh; Francis Agyei Amponsah
Journal:  PLoS One       Date:  2019-09-27       Impact factor: 3.240

3.  Shenkang Injection protects against diabetic nephropathy in streptozotocin (STZ)-induced mice through enhancement of anti-oxidant and anti-inflammatory activities.

Authors:  Bin Zhang; Xue-Lian Zhang; Chen-Yang Zhang; Gui-Bo Sun; Xiao-Bo Sun
Journal:  Chin Herb Med       Date:  2020-06-10

4.  Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice.

Authors:  Pei-Chun Chao; Cheng-Chin Hsu; Mei-Chin Yin
Journal:  Nutr Metab (Lond)       Date:  2009-08-14       Impact factor: 4.169

5.  Anti-Diabetic Effects of Madecassic Acid and Rotundic Acid.

Authors:  Yuan-Man Hsu; Yi-chih Hung; Lihong Hu; Yi-ju Lee; Mei-chin Yin
Journal:  Nutrients       Date:  2015-12-02       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.